Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PLRX Pliant Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: PLRX
Price (delayed)
$1.66
Market cap
$101.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.6
Enterprise value
$68.66M
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual
Highlights
PLRX's gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
Key stats
What are the main financial stats of PLRX
Market
Valuations
Earnings
Shares outstanding
61.39M
Market cap
$101.9M
Enterprise value
$68.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$234.91M
Net income
-$219.52M
EBIT
-$216.14M
EBITDA
-$210.49M
Free cash flow
-$176.71M
Per share
Balance sheet
Liquidity
EPS
-$3.6
EPS diluted
-$3.6
Free cash flow per share
-$2.89
Book value per share
$4.2
Revenue per share
$0
TBVPS
$5.63
Total assets
$344.77M
Total liabilities
$87.61M
Debt
$60.17M
Equity
$257.16M
Working capital
$282.99M
Debt to equity
0.23
Current ratio
11.03
Quick ratio
10.89
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.5%
Return on equity
-67.6%
Return on invested capital
-59.6%
Return on capital employed
-68.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLRX stock price
How has the Pliant Therapeutics stock price performed over time
Intraday
3.75%
1 week
22.96%
1 month
-1.78%
1 year
-86.33%
YTD
-87.4%
QTD
22.96%
Financial performance
How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$234.91M
Net income
-$219.52M
Gross margin
N/A
Net margin
N/A
PLRX's gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
The net income has contracted by 29% YoY and by 4.4% from the previous quarter
PLRX's operating income is down by 21% year-on-year and by 2.9% since the previous quarter
Price vs fundamentals
How does PLRX's price correlate with its fundamentals
Growth
What is Pliant Therapeutics's growth rate over time
Valuation
What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
0.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 25% year-on-year and by 3.7% since the previous quarter
PLRX's price to book (P/B) is 85% lower than its 5-year quarterly average of 2.6 and 75% lower than its last 4 quarters average of 1.6
The equity has contracted by 41% YoY and by 15% from the previous quarter
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Pliant Therapeutics business performance
The ROE has dropped by 93% year-on-year and by 19% since the previous quarter
Pliant Therapeutics's return on assets has shrunk by 65% YoY and by 15% QoQ
The company's return on invested capital has shrunk by 61% YoY and by 15% QoQ
Dividends
What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLRX.
Financial health
How did Pliant Therapeutics financials performed over time
The company's total assets fell by 34% YoY and by 13% QoQ
Pliant Therapeutics's current ratio has decreased by 32% YoY
Pliant Therapeutics's debt is 77% lower than its equity
PLRX's debt to equity has soared by 92% year-on-year and by 15% since the previous quarter
The equity has contracted by 41% YoY and by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.